|
Schizophrenia
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, both chymotrypsin-like activity and protein expression of 19S RP subunits, which facilitate ubiquitin-dependent degradation, were decreased in the cytosol-enriched fraction of SZ subjects.
|
30683941 |
2019 |
|
Schizophrenia
|
0.310 |
Biomarker
|
disease |
PSYGENET |
We furthermore identified genes with a significant trend correlating with age in the control (MLL3) or the schizophrenia group (SOX5, CTRL).
|
24287731 |
2014 |
|
Multiple Myeloma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Amide <b>6</b> showed an ideal profile since it was able to inhibit both the chymotrypsin-like activities of the immunoproteasome with <i>K</i><sub>i</sub> values of 4.90 µM and 4.39 µM for <i>β</i>1i and <i>β</i>5i, respectively, coupled with an EC<sub>50 </sub>=17.8 µM against MM.1R cells.
|
31307247 |
2019 |
|
Multiple Myeloma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
We analysed proteasome concentration and chymotrypsin-like (ChT-L) activity in 70 plasma and serum samples drawn from 28 patients at different treatment stages for multiple myeloma (MM) and 31 healthy volunteers.
|
29504425 |
2018 |
|
Multiple Myeloma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Syringolog-1 exhibited marked cytotoxicity against various MM cell lines and anti-tumor activity towards bortezomib (Btz)-resistant MM cells through the dual inhibition of chymotrypsin-like (β5 subunit) and trypsin-like (β2 subunit) activities.
|
29515784 |
2018 |
|
Multiple Myeloma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS.
|
29946907 |
2018 |
|
Multiple Myeloma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
The boronic acid dipeptide bortezomib inhibits the chymotrypsin-like activity of the 26S proteasome and shows significant therapeutic efficacy in multiple myeloma.
|
22308476 |
2012 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Breast cancer patients (BC, n = 59) scheduled to receive cancer therapy and healthy subjects (control group or CTRL, n = 49) were voluntarily recruited.
|
31230121 |
2020 |
|
Alzheimer's Disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
To discriminate AD from CTRL subjects, T-Tau/Aβ<sub>1-42</sub> ratio was the best biomarker, with a cut-off value of 1.12 (sensitivity 81.8% and specificity 92.9%).
|
31179518 |
2019 |
|
Alzheimer's Disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
Except for MALF, all methods detected a significant group difference between CTRL and AD, but none could find a significant difference between the CTRL and MCI.
|
31233953 |
2019 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Human kallikrein-related peptidases (KLKs) are a subgroup of trypsin and chymotrypsin-like serine peptidases that have emerged as promising prognosticators for many human types of cancer, being aberrantly expressed in cancerous tissues.
|
29883317 |
2018 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
The assessment of proteasome concentration and chymotrypsin-like (ChT-L) activity might constitute a new approach to diagnosis, prognosis and monitoring of anticancer treatment of patients with haematological malignancies and other diseases.
|
29504425 |
2018 |
|
Prostate carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
In conclusion, proteasomal chymotrypsin-like activity maybe a potential biomarker for prostate cancer, and may be suitable to supplement PSA in clinical application for prostate cancer diagnosis.
|
29552150 |
2018 |
|
Prostate carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Matrine inhibited proteasomal chymotrypsin‑like (CT‑like) activity in the prostate carcinoma cellular proteasome.
|
29845238 |
2018 |
|
Prostate carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Multivariate analysis was used to assess whether CT-like activity was a predictor of PCa progression.
|
25578495 |
2015 |
|
Alzheimer's Disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
We have discovered a new serine protease from the AD brain by polymerase chain reaction amplification of DNA sequences representing active site homologous regions of chymotrypsin-like enzymes.
|
9312124 |
1997 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
Breast cancer patients (BC, n = 59) scheduled to receive cancer therapy and healthy subjects (control group or CTRL, n = 49) were voluntarily recruited.
|
31230121 |
2020 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Intratumoural injection of AQP1 siRNA and CTRL siRNA was performed 10 days after tumour cell implantation.
|
29044946 |
2018 |
|
Malignant neoplasm of prostate
|
0.020 |
Biomarker
|
disease |
BEFREE |
In conclusion, proteasomal chymotrypsin-like activity maybe a potential biomarker for prostate cancer, and may be suitable to supplement PSA in clinical application for prostate cancer diagnosis.
|
29552150 |
2018 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Treponema denticola chymotrypsin-like proteinase may contribute to orodigestive carcinogenesis through immunomodulation.
|
29149107 |
2018 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
Human kallikrein-related peptidases (KLKs) are a subgroup of trypsin and chymotrypsin-like serine peptidases that have emerged as promising prognosticators for many human types of cancer, being aberrantly expressed in cancerous tissues.
|
29883317 |
2018 |
|
Cardiomyopathy, Familial Idiopathic
|
0.020 |
Biomarker
|
disease |
BEFREE |
The current study compared the efficacy of intracoronary administration of bone marrow mononuclear cells (BMMC) or mesenchymal stem cells (BMSC) in patients with DCM.Fifty-three patients with DCM and reduced (< 40%) left ventricular ejection fraction (LVEF), were randomized to intracoronary infusion of BMMC (BMMC group, n = 16) or BMSC (BMSC group, n = 17) or equal volume normal saline (CTRL group, n = 20).
|
28190794 |
2017 |
|
Malignant neoplasm of prostate
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Multivariate analysis was used to assess whether CT-like activity was a predictor of PCa progression.
|
25578495 |
2015 |
|
Cardiomyopathy, Familial Idiopathic
|
0.020 |
Biomarker
|
disease |
BEFREE |
LMNA was significantly underexpressed in mRNA from peripheral blood and myocardium of DCM(LMNAMut) patients versus DCM(LMNAWT) and CTRL(LMNAWT).
|
23062543 |
2012 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
These potential pharmacological benefits have been linked recently to the intrinsic ability of BBI to inhibit serine proteases, and the data suggest that both trypsin- and chymotrypsin-like proteases involved in carcinogenesis should be considered as potential targets of BBI.
|
21418025 |
2011 |